Proactive Investors
01 Sept 2026, 07:02 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Futura Medical warns that existing cash resources are expected to fund operations only until approximately October 2026. — An imminent liquidity crisis typically triggers strong sell-offs and necessitates urgent, potentially dilutive funding rounds.
-0.90The company appointed Market Performance Group as its new US commercial partner effective September 1, replacing Haleon. — Replacing a partner to rebuild momentum in the world's largest market is a positive strategic pivot for revenue growth.
+0.40FDA approval for Eroxon Intense is expected in the fourth quarter of 2026 following positive home user tests. — Regulatory approval for a stronger formulation expands the product pipeline and creates a catalyst for future sales.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The WSD4000 female sexual health gel showed 80% efficacy in home user tests, and the company is seeking global commercial partners. — Positive clinical data for a new product line increases the company's long-term valuation and partnership potential.
+0.20H1 revenue increased to £1.62 million from £1.00 million, though this includes a £1.40 million settlement with Haleon. — While revenue is up, the bulk of the growth is from a one-time settlement rather than organic operational growth.
+0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
2h ago
